

報道機関各位

2017年4月18日

新規注射用シデロフォアセファロスポリン抗菌薬 Cefiderocol および新規キャップ依存性
 エンドヌクレアーゼ阻害剤 S-033188 の臨床および非臨床試験結果の学会発表について
 —欧州臨床微生物学感染症学会議 (ECCMID) にて結果を発表—

塩野義製薬株式会社（本社：大阪市中央区、代表取締役社長：手代木 功）は、当社が創製し開発を進めている、新規注射用シデロフォアセファロスポリン抗菌薬 cefiderocol（一般名、開発番号：S-649266）および新規キャップ依存性エンドヌクレアーゼ阻害剤 S-033188 の臨床試験および非臨床試験結果を、オーストリア ウィーンで4月22日～25日に開催予定の第27回欧州臨床微生物学感染症学会議 The 27th European Congress of Clinical Microbiology and Infectious Diseases（以下「ECCMID」）において発表しますので、お知らせいたします。

ECCMIDにおいて予定されている発表の概要は、次のとおりです。

Cefiderocol		
セッション名	講演題目	要旨番号と発表情報
Late-breaker: Recent clinical trials	Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS*-cUTI)	Abstract #7582 Oral Presentation Saturday, April 22, 2017 17:09-17:20 PM Presenter: Simon Portsmouth
Advances in Japanese Chemotherapy	Mode of action of cefiderocol, a novel siderophore cephalosporin, active against highly resistant Gram-negative bacteria including carbapenem-resistant strains of Enterobacteriaceae and non-fermenting bacteria	Abstract #3177 Oral Presentation Monday, April 24, 2017 14:54-15:04 PM Presenter: Yoshinori Yamano
Cefiderocol	<i>In vitro</i> activity of cefiderocol against globally collected carbapenem-resistant Gram-negative bacteria including isolates resistant to ceftazidime/avibactam, ceftolozane/tazobactam and colistin: SIDERO-CR-2014/2016 study	Poster #1316 Poster Presentation Monday, April 24, 2017 12:30-13:30 PM Presenter: Yoshinori Yamano
	Surveillance of cefiderocol <i>in vitro</i> activity against Gram-negative clinical isolates collected in Europe: SIDERO-WT-2014	Poster #1314 Poster Presentation Monday, April 24, 2017 12:30-13:30 PM Presenter: Masakatsu Tsuji

	The <i>in vitro</i> activity of cefiderocol, a siderophore cephalosporin, against a global collection of <i>Stenotrophomonas maltophilia</i>	Poster #1313 Poster Presentation Monday, April 24, 2017 12:30-13:30 PM Presenter: Masakatsu Tsuji
--	--	---

* *Acinetobacter, Pseudomonas, Escherichia, Klebsiella and Stenotrophomonas*

S-033188		
セッション名	講演題目	要旨番号と発表情報
Advances in Japanese chemotherapy	Pharmacokinetic/pharmacodynamic analysis of S-033188, an influenza Cap-dependent endonuclease inhibitor, from a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza	Abstract #1033 Oral Presentation Monday, April 24, 2017 15:18-15:28 PM Presenter: Takeki Uehara
Novel and improved therapeutical approaches to viral infections	One day oral dosing of S-033188, a novel inhibitor of influenza virus Cap-dependent endonuclease, exhibited significant reduction of viral titer and prolonged survival in mice infected with influenza B virus	Poster #1971 Poster Presentation Tuesday, April 25, 2017 12:30-13:30 PM Presenter: Takao Shishido
	Pharmacokinetic and pharmacodynamic analysis of S-033188/S-033447, a novel inhibitor of influenza virus Cap-dependent endonuclease, in mice infected with influenza A virus	Poster #1973 Poster Presentation Tuesday, April 25, 2017 12:30-13:30 PM Presenter: Takeshi Noshi
	Inhibitory effect of S-033188/S-033447, a novel inhibitor of influenza virus Cap-dependent endonuclease, against highly pathogenic avian influenza virus A/H5N1	Poster #1974 Poster Presentation Tuesday, April 25, 2017 12:30-13:30 PM Presenter: Keiichi Taniguchi

以上

[お問合せ先]

塩野義製薬株式会社 広報部

TEL : 06-6209-7885 FAX : 06-6229-9596